Anktiva plus BCG aims to treat BCG-unresponsive NMIBC with papillary ... This novel mechanism of action, which mimics the biology of the dendritic cell, begins the evolution of immunotherapy beyond T ...

A prior phase II trial had shown that BCG revaccination in teens led to 45.4% efficacy in reversion from positive to negative ...

Academic researchers in Massachusetts believe the standard BCG (bacillus Calmette-Guérin) vaccine could have a remarkable second use: a treatment to reverse advanced type 1 diabetes. The cause of ...

The unusual molecular makeup of Borrelia burgdorferi, which causes Lyme disease, may hold clues for understanding and treating the tick-borne disease.

in combination with the Bacillus Calmette-Guérin (BCG) vaccine for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary disease. According to ImmunityBio, the move ...

Vaccines save millions of lives every year, but there is still an urgent need for more efficient vaccines. Strategies to combat serious outbreaks of viral infections are particularly important. Such ...

The bacillus Calmette–Guérin (BCG) vaccine, initially developed to provide protection against TB, also protects against leprosy; and the magnitude of this effect varies. Previous meta-analyses ...

The complete response (CR) rate to the combination of the interleukin (IL)-15 superagonist nogapendekin alfa inbakicept-pmln (Anktiva®) and bacillus Calmette-Guerin (BCG) in BCG-unresponsive ...

BCG (Bacillus Calmette - Guerin) vaccine is made from a treated (attenuated) live strain of bacterium derived from Mycobacterium bovis, a bacterium which typically causes tuberculosis (TB ...